Advertisement

Skin of Color pp 263-273 | Cite as

Botulinum Toxin A

  • Elena Jones
  • Carlos A. Charles
Chapter

Abstract

There is a trend toward greater use of cosmetic procedures by ethnic minorities. The greatest level of increased interest is among Latino and African American patients, with Latino patients leading all minority groups in the number of cosmetic procedures performed in 2008. African American and Asian American patients closely trail Latino patients, comprising 8% and 7% of all of the cosmetic procedures performed in 2008. The most commonly requested surgical procedures are nose reshaping, breast reduction, and liposuction, whereas botulinum toxin A, facial fillers, and chemical peels are the most commonly requested minimally invasive procedures.

Keywords

Botulinum Toxin Cervical Dystonia African American Patient Botulinum Toxin Type Botulinum Neurotoxin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Erbguth FJ. Historical notes on botulinum, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord. 2004;19:S2–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Cherington M. Clinical spectrum of botulinum. Muscle Nerve. 1998;21:701–10.PubMedCrossRefGoogle Scholar
  3. 3.
    Bengston IA. Studies on organisms concerned as causative factors in botulinum. Hyg Lab Bull. 1924;136:101.Google Scholar
  4. 4.
    Carruthers JD, Carruthers A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18:17–21.PubMedCrossRefGoogle Scholar
  5. 5.
    Glogau RG. Botulinum A neurotoxin for axillary hyperhidrosis: no sweat Botox. Dermatol Surg. 1998;24:817–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Curruthers A, Carruthers J. Botulinum toxin type A. J Am Acad Dermatol. 2005;53:284–90.CrossRefGoogle Scholar
  7. 7.
    Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology. 2000;55 Suppl 5:S29–35.PubMedGoogle Scholar
  8. 8.
    Schwetz BA. First drug for cervical dystonia. JAMA. 2001;285:724.PubMedCrossRefGoogle Scholar
  9. 9.
    Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of Neurobloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;7:1431–8.CrossRefGoogle Scholar
  10. 10.
    Baumann L, Slezinger A, Halem M, et al. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of axillary hyperhidrosis. Int J Dermatol. 2005;44:418–24.PubMedCrossRefGoogle Scholar
  11. 11.
    Carruthers A, Carruthers J, Kiena K. Botulinum A exotoxin use in clinical dermatology. J Am Acad Dermatol. 1996;34:788–95.PubMedCrossRefGoogle Scholar
  12. 12.
    Tsui JKC. Botulinum toxin as a therapeutic agent. Pharmacol Ther. 1996;72:13–24.PubMedCrossRefGoogle Scholar
  13. 13.
    Frankel AS. Botox rejuvenation for the periorbital region. Facial Plast Surg. 1999;15:255–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Klein AW. Complications and adverse reactions with the use of botulinum toxin. Semin Cutan Med Surg. 2001;20:109–20.PubMedCrossRefGoogle Scholar
  15. 15.
    Roehm PC, Perry JD, Girkin CA, et al. Prevalence of periocular depigmentation after repeated botulinum toxin A injections in African American patients. J Neuroophthalmol. 1999;19:7–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg. 2003;29:549–56.PubMedCrossRefGoogle Scholar
  17. 17.
    Wollina U, Konrad H. Managing adverse events associated with botulinum toxin A: a focus on cosmetic procedures. Am J Clin Dermatol. 2005;6:141–50.PubMedCrossRefGoogle Scholar
  18. 18.
    Carruthers A, Carruthers JA. Botulinum toxin in the treatment of glabellar frown lines and other facial wrinkles. In: Jankivic J, Hallet M, editors. Therapy with botulinum toxin. New York: Marcel Decker Inc; 1994. p. 577–95.Google Scholar
  19. 19.
    Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol. 2004;22:66–75.PubMedCrossRefGoogle Scholar
  20. 20.
    Atamoros FP. Botulinum toxin in the lower third of the face. Clin Dermatol. 2003;21:505–12.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of DermatologySt. Luke’s – Roosevelt HospitalNew YorkUSA
  2. 2.Department of DermatologyWeill Medical College of Cornell University, New York Presbyterian Hospital/CornellNew YorkUSA

Personalised recommendations